CN117244021A - 一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法 - Google Patents
一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法 Download PDFInfo
- Publication number
- CN117244021A CN117244021A CN202311389433.6A CN202311389433A CN117244021A CN 117244021 A CN117244021 A CN 117244021A CN 202311389433 A CN202311389433 A CN 202311389433A CN 117244021 A CN117244021 A CN 117244021A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- blood
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 97
- 239000008280 blood Substances 0.000 title claims abstract description 97
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000001603 reducing effect Effects 0.000 title claims abstract description 46
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 45
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229940116269 uric acid Drugs 0.000 title claims abstract description 44
- 230000036772 blood pressure Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 150000002632 lipids Chemical class 0.000 title claims description 12
- 239000003814 drug Substances 0.000 claims abstract description 103
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 239000000706 filtrate Substances 0.000 claims description 41
- 240000000249 Morus alba Species 0.000 claims description 31
- 235000008708 Morus alba Nutrition 0.000 claims description 31
- 238000001914 filtration Methods 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000008367 deionised water Substances 0.000 claims description 19
- 229910021641 deionized water Inorganic materials 0.000 claims description 19
- 244000281702 Dioscorea villosa Species 0.000 claims description 18
- 238000002137 ultrasound extraction Methods 0.000 claims description 18
- 235000004879 dioscorea Nutrition 0.000 claims description 17
- 235000013399 edible fruits Nutrition 0.000 claims description 17
- 244000036905 Benincasa cerifera Species 0.000 claims description 16
- 235000011274 Benincasa cerifera Nutrition 0.000 claims description 16
- 241000830535 Ligustrum lucidum Species 0.000 claims description 16
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 15
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 15
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 15
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 15
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 15
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 15
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 15
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 15
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 15
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 15
- 241001523681 Dendrobium Species 0.000 claims description 15
- 241001643642 Viticis Species 0.000 claims description 15
- 241000305492 Gastrodia Species 0.000 claims description 14
- 238000009835 boiling Methods 0.000 claims description 14
- 238000011049 filling Methods 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 14
- 241000717679 Mosla Species 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 238000001291 vacuum drying Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 235000011194 food seasoning agent Nutrition 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 229940013618 stevioside Drugs 0.000 claims description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 7
- 235000019202 steviosides Nutrition 0.000 claims description 7
- 244000189123 Rumex japonicus Species 0.000 claims description 6
- 235000005247 Rumex japonicus Nutrition 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 240000000171 Crataegus monogyna Species 0.000 claims 4
- 240000002948 Ophiopogon intermedius Species 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 38
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 44
- 239000013641 positive control Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 206010020772 Hypertension Diseases 0.000 description 12
- 244000248557 Ophiopogon japonicus Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 241001092040 Crataegus Species 0.000 description 11
- 201000001431 Hyperuricemia Diseases 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 8
- 238000000465 moulding Methods 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 230000003345 hyperglycaemic effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 240000004638 Dendrobium nobile Species 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 210000002254 renal artery Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- 241000131458 Elsholtzia Species 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 240000004934 Vitex trifolia Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000026010 Dendrobium candidum Species 0.000 description 1
- 244000269590 Dendrobium chrysanthum Species 0.000 description 1
- 244000030990 Dendrobium fimbriatum Species 0.000 description 1
- 241000229499 Dendrobium loddigesii Species 0.000 description 1
- 241001076416 Dendrobium tosaense Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 241000743946 Dioscorea gracilis Species 0.000 description 1
- 241000908494 Dioscorea nipponica Species 0.000 description 1
- 235000017008 Dioscorea nipponica Nutrition 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241001448421 Ophiopogon jaburan Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 241000219053 Rumex Species 0.000 description 1
- 235000021501 Rumex crispus Nutrition 0.000 description 1
- 244000207667 Rumex vesicarius Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种具有同时发挥显著的降血糖、血脂、血压、尿酸作用的中药组合提取物及其制备方法。所述的中药组合提取物的中药原料为:萆薢、冬瓜皮、山楂、羊蹄、麦冬、天麻、石斛、女贞子、香薷、蔓荆子、桑叶。本发明组合提取物配伍合理,共同发挥祛风化湿、清利湿热、活血化瘀等功效,制备方法简单,易于服用,成本低,无毒副作用,疗效明显,能同时具有显著的降血糖、血脂、血压、尿酸的作用。
Description
技术领域
本发明属于中药技术领域,具体涉及一种降血糖、血脂、血压、尿酸的中药组合提取物。
背景技术
随着人们生活水平的提高以及人们生活方式、饮食习惯的改变,各种严重危害人类生命的疾病患病率逐年攀升,其中,“四高”的发病率明显上升,严重威胁人们的健康。说到“四高”,大家可能只知道常见的“三高”指的是“高血压、高血糖、高血脂”,那第四高是什么呢?高尿酸症是与高血压、高血脂、高血糖等密切相关的代谢综合征,被称为“第四高”。近年来,此病的发病率呈上升趋势,而且,高尿酸症患者往往也合并有其他“三高”。高血压损伤大脑、肾脏,高血糖危害全身,高血脂影响心脏血管,尿酸危害肾脏功能,同时,高血压、高血糖、高血脂,都是引起心脑血管疾病的主要危险因素,三者密切相关,相互促进;高尿酸血症与代谢综合征关系密切,如果血液中尿酸长期升高,会使尿酸盐沉积在关节及其周围组织,脚趾、脚踝、膝关节等处会出现急性的剧烈疼痛、红肿等现象。
目前治疗“四高”主要依靠降血糖、血脂、血压、尿酸的药物和饮食控制。药物降三高以及降尿酸的效果虽然较为明显,但是,长期服用降血糖、血脂、血压、尿酸的药物容易产生副作用,或是存在严重的不良反应,尤其对肝、肾损伤严重,患者依从性差,且停药血糖、血脂、血压、尿酸水平极易反弹,远期疗效不理想。饮食控制是必要的,但是过于严格的饮食控制使得患者饮食过于单一且失去对美味的享受。且目前市场上能同时具有降三高和降尿酸的药品、保健品或食品添加物很少,一般都是只能单独的降三高或降尿酸,而不能同时起到很好的降血糖、血脂、血压、尿酸的作用。
中药作为传统的治疗药物,其具有纯天然、药效显著,且标本兼治的作用,因此,急需开发出一种能同时降三高和降尿酸,且治疗效果显著、无毒副作用、原料便宜易得、制备简单的中药组合提取物。
发明内容
针对现有技术的不足,本发明的目的在于提供一种中药组合提取物,尤其提供一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法和应用。
为达到此发明目的,本发明采用以下技术方案:
本发明所涉及的各项中药均可从一般中药店购得,其规格符合中国药典标准。
第一方面,本发明提供一种降血糖、血脂、血压、尿酸的中药组合提取物,所述中药原料为:萆薢10-30份、冬瓜皮5-25份、山楂5-25份、羊蹄10-30份、麦冬5-25份、天麻5-20份、石斛5-20份、女贞子10-25份、香薷10-30份、蔓荆子5-25份、桑叶5-20份。
优选地,所述中药原料为:萆薢15-30份、冬瓜皮10-25份、山楂10-25份、羊蹄15-30份、麦冬10-25份、天麻8-20份、石斛8-20份、女贞子12-25份、香薷15-30份、蔓荆子8-23份、桑叶8-18份。
更优选地,所述中药原料为:萆薢25份、冬瓜皮20份、山楂25份、羊蹄28份、麦冬22份、天麻16份、石斛15份、女贞子14份、香薷25份、蔓荆子15份、桑叶15份。
更优选地,所述中药原料为:萆薢30份、冬瓜皮22份、山楂25份、羊蹄26份、麦冬20份、天麻15份、石斛13份、女贞子21份、香薷20份、蔓荆子20份、桑叶16份。
第二方面,本发明提供一种所述的降血糖、血脂、血压、尿酸的中药组合提取物的制备方法,包括以下步骤:
S1.按重量份取桑叶,除杂后真空干燥,再粉碎为粗粉,过80-100目筛,加入粗粉总重量4-8倍量的去离子水,在40-60℃下超声提取1-3次,每次1-4 h,超声提取的功率为110-180W,提取完成后合并滤液,过滤得到桑叶提取液,备用;
S2.按重量份取萆薢、冬瓜皮、山楂、羊蹄、麦冬、天麻、石斛、女贞子、香薷、蔓荆子,清洗干净后真空干燥,再粉碎为粗粉,过60-80目筛,过筛后将上述粗粉加入至步骤S1中得到的桑叶提取液中,煮沸后小火继续煎煮1.5-5 h,过滤,得到滤液备用,滤渣加入2-5倍量的去离子水煮沸后继续煎煮0.5-3 h,过滤得到滤液,合并两次滤液,室温下冷却,得到中药提取液,备用;
S3.取上述中药提取液,经150-250目筛过滤得滤液,真空浓缩至原来体积的1/2-1/3,加入甜菊糖调味,混合均匀得混合药液,即得所述中药组合提取物。
进一步地,将所述中药组合提取物制备为口服液:取所述中药组合提取物,灌封至玻璃口服液瓶中,灌装轧盖后,紫外灭菌10-30 min,包装,即得所述口服液。
进一步地,步骤S1中过90目筛,超声提取2次,第1次加入6倍量的去离子水提取4h,第2次加入4倍量去离子水提取2 h。
进一步地,步骤S1中提取温度为50℃,提取功率为150W。
进一步地,步骤S2中第1次煎煮时间为4 h,第2次为2.5 h。
第三方面,本发明提供一种所述的中药组合提取物在制备降血糖、血脂、血压、尿酸的药物中的应用。
其中,萆薢为薯蓣科植物粉背薯蓣、叉蕊薯蓣、山萆薢或纤细薯蓣等的块茎。具有祛风湿、利湿浊的功效。主膏淋;白浊;带下;疮疡;湿疹;风湿痹痛。
其中,冬瓜皮为葫芦科植物冬瓜Benincasa his pida(Thunb.)Cogn.的干燥外层果皮。具有利尿消肿的功效,用于水肿胀满,小便不利,暑热口渴,小便短赤。
其中,山楂为蔷薇科植物山里红Crataegus pinnatifida Bge.var.majorN.E.Br.或山楂Crataegus pinnatifida Bge.的干燥成熟果实。具有消食健胃,行气散瘀的功效。用于肉食积滞,胃脘胀满,泻痢腹痛,瘀血经闭,产后瘀阻,心腹刺痛,疝气疼痛;高脂血症。焦山楂消食导滞作用增强。用于肉食积滞,泻痢不爽。
其中,羊蹄为蓼科酸模属植物皱叶酸模Rumex crispus L 或羊蹄R. japonicusHoutt.,以根或全草入药。具有清热解毒,止血,通便,杀虫的功效。用于鼻出血,功能性子宫出血,血小板减少性紫癜,慢性肝炎,肛门周围炎,大便秘结;外用治外痔,急性乳腺炎,黄水疮,疖肿,皮癣。
其中,麦冬为百合科植物麦冬(沿阶草)Ophiopogon japonicus (Thunb.)Ker-Gawl.的干燥块根。具有养阴生津,润肺清心的功效。用于肺燥干咳。虚痨咳嗽,津伤口渴,心烦失眠,内热消渴,肠燥便秘;咽白喉。
其中,天麻为兰科植物天麻Gastrodia elata Blume. 的干燥块茎。具有平肝息风止痉的功效。用于头痛眩晕,肢体麻木,小儿惊风,癫痫抽搐,破伤风。
其中,石斛为兰科植物环草石斛Dendrobium loddigesii Rolfe. 、马鞭石斛Dendrobium fimbriatum Hook. var. oculatum Hook . 、黄草石斛Dendrobiumchrysanthum Wall. 、铁皮石斛Dendrobium candidum Wall. ex Lindl. 或金钗石斛Dendrobium nobile Lindl. 的新鲜或干燥茎。具有益胃生津,滋阴清热的功效。用于阴伤津亏,口干烦渴,食少干呕,病后虚热,目暗不明。
其中,女贞子为木犀科植物女贞Ligustrum lucidum Ait. 的干燥成熟果实。具有滋补肝肾,明目乌发的功效。用于眩晕耳鸣,腰膝酸软,须发早白,目暗不明。
其中,香薷为唇形科植物石香薷Mosla chinensis Maxim.的干燥地上部分。具有发汗解表,和中利湿的功效。用于暑湿感冒,恶寒发热,头痛无汗,腹痛吐泻,小便不利。
其中,蔓荆子为马鞭草科植物单叶蔓荆Vitex trifolia L. var. simplicifoliaCham. 或蔓荆Vitex trifolia L.的干燥成熟果实。具有疏散风热,清利头目的功效。用于风热感冒头痛,齿龈肿痛,目赤多泪,目暗不明,头晕目眩。
其中,桑叶为桑科植物桑Morus alba L. 的干燥叶。具有疏散风热,清肺润燥,清肝明目的功效。用于风热感冒,肺热燥咳,头晕头痛,目赤昏花。
本发明组合物的组方分析:四高症在中医归归属于“痰”“湿”“瘀”“火”“毒”的范畴,部分高尿酸血症可引起痛风,痛风的临床特点可归于中医痹症之“热痹”,因此“四高症”一般以泄化湿浊瘀毒、祛风化湿、清利湿热、活血化瘀、消肿止痛为主。本发明组合物以萆薢、香薷、桑叶为君药,重在祛风止痛、清热除湿,其中,萆薢总皂苷具有显著的降低尿酸、抗炎的作用,桑叶提取物具有显著的降血糖、降血脂的作用,三者共同发挥作用,具有显著的降“四高”的效果;以冬瓜皮、山楂、羊蹄为臣药,清热、解毒、行气、散淤,在增强君药降血糖、血脂、尿酸等作用的同时,还发挥降血糖、降血脂等功效;以天麻、女贞子、麦冬为佐药,养阴生津、滋补肝肾,能降血糖、降血脂、抗氧化、保护心血管系统;以石斛、蔓荆子为使药,滋阴清热、疏风散热,不仅具有降三高的作用,还可以提高机体免疫力,佐使药进一步增强君臣药对于血糖、血脂、血压、尿酸的调节作用。诸药搭配,协同作用,在祛风止痛、清热除湿的基础上,辅以清热解毒、行气散淤、消肿止痛等,共同达到降血脂、降血糖、降血压、降尿酸的功效,还可以缓解因为四高症引起的关节肿痛的症状。
本发明的有益效果为:本发明提供的一种降血糖、血脂、血压、尿酸的中药组合提取物,中药原料简单易得,符合“君臣佐使”原则,共同发挥祛风化湿、清利湿热、活血化瘀等功效,制备方法简单,制成的口服液易于服用,成本低,疗效明显,能同时具有显著的降血糖、血脂、血压、尿酸的作用,具有实用性和社会效益。
具体实施方式
为了更好地理解本发明,下面结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限制本发明的范围。
实施例1:一种降血糖、血脂、血压、尿酸的中药组合提取物,由以下原料组成:萆薢10份、冬瓜皮5份、山楂5份、羊蹄10份、麦冬5份、天麻5份、石斛5份、女贞子10份、香薷10份、蔓荆子5份、桑叶5份。
一种所述降血糖、血脂、血压、尿酸的中药组合提取物的制备方法,包括以下步骤:
S1.按重量份取桑叶,除杂后真空干燥,再粉碎为粗粉,过80目筛,加入粗粉总重量4倍量的去离子水,在40℃下超声提取1次,提取时间1 h,超声提取的功率为110W,提取完成后合并滤液,过滤得到桑叶提取液,备用;
S2.按重量份取萆薢、冬瓜皮、山楂、羊蹄、麦冬、天麻、石斛、女贞子、香薷、蔓荆子,清洗干净后真空干燥,再粉碎为粗粉,过60目筛,过筛后将上述粗粉加入至步骤S1中得到的桑叶提取液中,煮沸后小火继续煎煮1.5h,过滤,得到滤液备用,滤渣加入2倍量的去离子水煮沸后继续煎煮0.5h,过滤得到滤液,合并两次滤液,室温下冷却,得到中药提取液,备用;
S3.取上述中药提取液,经150目筛过滤得滤液,真空浓缩至原来体积的1/2,加入甜菊糖调味,混合均匀得混合药液,即得所述中药组合提取物。
还包括将所述中药组合提取物制备为口服液的步骤S4:
S4.取所述中药组合提取物,灌封至玻璃口服液瓶中,灌装轧盖后,紫外灭菌10min,包装,即得所述中药组合提取物。
实施例2:一种降血糖、血脂、血压、尿酸的中药组合提取物,由以下原料组成:萆薢30份、冬瓜皮25份、山楂25份、羊蹄30份、麦冬25份、天麻20份、石斛20份、女贞子25份、香薷30份、蔓荆子25份、桑叶20份。
一种所述降血糖、血脂、血压、尿酸的中药组合提取物的制备方法,包括以下步骤:
S1.按重量份取桑叶,除杂后真空干燥,再粉碎为粗粉,过100目筛,加入粗粉总重量8倍量的去离子水,在60℃下超声提取3次,第1-2次均提取4 h,第3次提取1.5 h,超声提取的功率均为180W,提取完成后合并滤液,过滤得到桑叶提取液,备用;
S2.按重量份取萆薢、冬瓜皮、山楂、羊蹄、麦冬、天麻、石斛、女贞子、香薷、蔓荆子,清洗干净后真空干燥,再粉碎为粗粉,过80目筛,过筛后将上述粗粉加入至步骤S1中得到的桑叶提取液中,煮沸后小火继续煎煮5 h,过滤,得到滤液备用,滤渣加入5倍量的去离子水煮沸后继续煎煮3 h,过滤得到滤液,合并两次滤液,室温下冷却,得到中药提取液,备用;
S3.取上述中药提取液,过250目筛过滤得滤液,真空浓缩至原来体积的1/3,加入甜菊糖调味,混合均匀得混合药液;
S4.取所述混合药液,灌封至玻璃口服液瓶中,灌装轧盖后,紫外灭菌30 min,包装,即得所述中药组合提取物。
实施例3:一种降血糖、血脂、血压、尿酸的中药组合提取物,由以下原料组成:萆薢25份、冬瓜皮21份、山楂14份、羊蹄12份、麦冬17份、天麻18份、石斛11份、女贞子17份、香薷25份、蔓荆子18份、桑叶15份。
一种所述降血糖、血脂、血压、尿酸的中药组合提取物的制备方法,包括以下步骤:
S1.按重量份取桑叶,除杂后真空干燥,再粉碎为粗粉,过80目筛,加入粗粉总重量5倍量的去离子水,在55℃下超声提取2次,第1次提取3 h,第二次提取2 h,超声提取的功率均为160W,提取完成后合并滤液,过滤得到桑叶提取液,备用;
S2.按重量份取萆薢、冬瓜皮、山楂、羊蹄、麦冬、天麻、石斛、女贞子、香薷、蔓荆子,清洗干净后真空干燥,再粉碎为粗粉,过70目筛,过筛后将上述粗粉加入至步骤S1中得到的桑叶提取液中,煮沸后小火继续煎煮3.5 h,过滤,得到滤液备用,滤渣加入3倍量的去离子水煮沸后继续煎煮2 h,过滤得到滤液,合并两次滤液,室温下冷却,得到中药提取液,备用;
S3.取上述中药提取液,经200目筛过滤得滤液,真空浓缩至原来体积的1/2,加入甜菊糖调味,混合均匀得混合药液;
S4.取所述混合药液,灌封至玻璃口服液瓶中,灌装轧盖后,紫外灭菌20 min,包装,即得所述即得所述中药组合提取物。
实施例4:一种降血糖、血脂、血压、尿酸的中药组合提取物,由以下原料组成:萆薢30份、冬瓜皮22份、山楂25份、羊蹄26份、麦冬20份、天麻15份、石斛13份、女贞子21份、香薷20份、蔓荆子20份、桑叶16份。
一种所述降血糖、血脂、血压、尿酸的中药组合提取物的制备方法,包括以下步骤:
S1.按重量份取桑叶,除杂后真空干燥,再粉碎为粗粉,过100目筛,加入粗粉总重量7倍量的去离子水,在45℃下超声提取3次,每次2.5 h,超声提取的功率为170W,提取完成后合并滤液,过滤得到桑叶提取液,备用;
S2.按重量份取萆薢、冬瓜皮、山楂、羊蹄、麦冬、天麻、石斛、女贞子、香薷、蔓荆子,清洗干净后真空干燥,再粉碎为粗粉,过80目筛,过筛后将上述粗粉加入至步骤S1中得到的桑叶提取液中,煮沸后小火继续煎煮3.5h,过滤,得到滤液备用,滤渣加入4倍量的去离子水煮沸后继续煎煮2.5 h,过滤得到滤液,合并两次滤液,室温下冷却,得到中药提取液,备用;
S3.取上述中药提取液,经220目筛过滤得滤液,真空浓缩至原来体积的1/3,加入甜菊糖调味,混合均匀得混合药液,即得所述中药组合提取物。
还包括将所述中药组合提取物制备为口服液的步骤S4:
S4.取所述中药组合提取物,灌封至玻璃口服液瓶中,灌装轧盖后,紫外灭菌30min,包装,即得所述口服液。
实施例5:一种降血糖、血脂、血压、尿酸的中药组合提取物,由以下原料组成:萆薢25份、冬瓜皮20份、山楂25份、羊蹄28份、麦冬22份、天麻16份、石斛15份、女贞子14份、香薷25份、蔓荆子15份、桑叶15份。
一种所述降血糖、血脂、血压、尿酸的中药组合提取物的制备方法,包括以下步骤:
S1.按重量份取桑叶,除杂后真空干燥,再粉碎为粗粉,过90目筛,加入粗粉总重量6倍量的去离子水,在50℃下超声提取4 h,过滤后,滤渣加入4倍量去离子水继续在50℃下超声提取2 h,超声提取的功率均为150W,提取完成后合并滤液,过滤得到桑叶提取液,备用;
S2.按重量份取萆薢、冬瓜皮、山楂、羊蹄、麦冬、天麻、石斛、女贞子、香薷、蔓荆子,清洗干净后真空干燥,再粉碎为粗粉,过80目筛,过筛后将上述粗粉加入至步骤S1中得到的桑叶提取液中,煮沸后小火继续煎煮4 h,过滤,得到滤液备用,滤渣加入3倍量的去离子水煮沸后继续煎煮2.5 h,过滤得到滤液,合并两次滤液,室温下冷却,得到中药提取液,备用;
S3.取上述中药提取液,经250目筛过滤得滤液,真空浓缩至原来体积的1/2,加入甜菊糖调味,混合均匀得混合药液,即得所述中药组合提取物;
还包括将所述中药组合提取物制备为口服液的步骤S4:
S4.取所述中药组合提取物,灌封至玻璃口服液瓶中,灌装轧盖后,紫外灭菌25min,包装,即得口服液。
实施例6:本发明中药组合提取物对高血糖模型大鼠降血糖和降血脂的作用
一、实验动物:SD大鼠50只,雌雄各半,体重240-260g,从北京维通利华实验动物技术有限公司购入。
二、实验药物及分组:分组为空白对照组、阳性对照组、模型组、低剂量治疗组、高剂量治疗组。取本发明实施例5中制备得到的中药组合提取物作为治疗组所用药物,低剂量治疗组、高剂量治疗组的给药剂量分别为2 g/kg、4 g/kg;阳性对照组给与二甲双胍溶液,给药剂量为200 mg/kg,模型组和空白对照组分别给予4 g/kg的生理盐水。
三、实验方法:
(1)造模:50只大鼠适应性喂养3 d后,禁食5 h,测量空腹血糖,以此值作为基础血糖值。随后随机选取40只实验大鼠禁食24 h(期间可自由饮水),随后造模大鼠使用高脂饲料喂养喂饲,喂养2周后,在高脂饲料基础上腹腔注射新鲜配制的四氧嘧啶140 mg/(kg•bw)造模,连续注射 7 d 后,大鼠禁食不禁水 5 h 后测血糖,选取血糖值大于 11.1 mmol/L作为高血糖模型成功大鼠。
(2)高血糖模型空腹血糖测定:在高血糖造模成功的高血糖 SD 大鼠中随机选取出24只,随机分为4组,每组6只。其中给药组给予本发明的中药组合提取物,低剂量治疗组(剂量为2 g/kg)、高剂量治疗组(剂量为4 g/kg),阳性对照组给予二甲双胍溶液(剂量为200 mg/kg),模型组给予生理盐水(剂量为4 g/kg),另外随机取未造模大鼠6只作为空白对照组,给予生理盐水(剂量为4 g/kg)。每组连续灌胃14 d,在第0 d、7 d、14 d时测定大鼠空腹血糖值(每次测定前禁不禁水食5 h),比较各组大鼠的血糖值。
(3)血脂指标的测定:在高血糖模型SD大鼠空腹血糖测定完成后,腹腔注射戊巴比妥钠(给药剂量为 40 mg/kg, 注射剂量为 10 mL/(kg•bw))麻醉大鼠,腹主动脉采血,离心15 min,取上清液待测。按照对应试剂盒以果糖胺法测定 GSP、放射免疫方法检测血清TC、TG、HDL-C 和 LDL-C 浓度。
四、实验结果:
(1)血糖测定结果如表1所示,可以看出,第0 d时,与空白组相比,模型组、低剂量治疗组、高剂量治疗组、阳性对照组大鼠的血糖值均明显升高,说明造模成功。到了第7 d、14 d时,与模型组相比,本发明组合物组高、低剂量以及阳性对照组的血糖水平明显下降,且到了第14 d时,本发明组合提取物高剂量组降血糖水平还高于阳性对照二甲双胍组,说明本发明中药组合提取物具有显著的降血糖作用。
表1 对高血糖模型大鼠空腹血糖的影响(平均数±标准差,mmol/L)
注:与模型组比较,*P <0.05, **P <0.01;与空白组比较,#P <0.05, ##P <0.01(下同)
(2)血清TC、TG、HDL-C 和 LDL-C 测定结果如表2所示,可见,与空白组相比,模型组、低剂量治疗组、高剂量治疗组、阳性对照组大鼠的TC、TG、LDL-C 浓度升高,HDL-C 水平降低,说明高血脂模型成功。到了第14 d时,与模型组相比,本发明组合物组高、低剂量以及阳性对照组的TC、TG、LDL-C 浓度水平明显下降,HDL-C 水平明显上升,且本发明组合提取物高剂量组TC、TG、LDL-C 浓度水平下降优于阳性对照组,HDL-C 水平升高优于阳性对照组,说明本发明中药组合提取物具有显著的降血脂作用。
表2 对高血糖模型大鼠血脂的影响(平均数±标准差,mmol/L)
实施例7:本发明中药组合提取物对高尿酸血症模型大鼠尿液和血清中尿酸的影响
一、实验动物:SD大鼠30只,雌雄各半,体重240-260g,从北京维通利华实验动物技术有限公司购入。
二、实验药物及分组:同上实施例6。
三、实验方法:大鼠适应性喂养3 d后,随机分为5组,每组6只。实验期间,除空白组外,其余各组大鼠每天灌胃腺嘌呤(100 mg·kg-1)和乙胺丁醇(250 mg·kg-1)混悬液(溶剂为 0.5% CMC-Na),空白组给予相同体积的0.5% CMC-Na溶液,连续23 d。造模第5 d开始灌胃给药,每天1次,其中,低剂量治疗组(剂量为2 g/kg)、高剂量治疗组(剂量为4 g/kg)给予本发明实施例5中制备的中药组合提取物,阳性对照组给予二甲双胍溶液(剂量为200mg/kg),模型组和空白对照组均给予生理盐水(剂量为4 g/kg)。在末次给药2 h 后,用代谢笼收取各组大鼠的尿液,测定尿液中尿酸的含量。尿液收集完后,大鼠麻醉后腹主动脉取血,置于阴凉柜中静置半小时后,离心机分离血清(4℃,3 500 r·min-1 离心10 min,离心半径 6 cm),取上清液,存于-40℃备用,用脲酶法检测血BUN含量。
四、实验结果:结果如表3所示,可以看出,与空白组相比,模型组尿液中尿酸含量显著降低,而血清中BUN含量显著升高。与模型组相比,本发明组合物组高、低剂量以及阳性对照组的尿液中尿酸含量显著升高,而血清BUN含量显著降低血糖水平明显下降,并且本发明组合提取物高剂量组逆转尿酸水平的作用较二甲双胍更明显,说明本发明中药组合提取物具有显著的改善高尿酸血症作用。
表3 对高尿酸血症模型大鼠尿液和血清中尿酸的影响(平均数±标准差,n = 6)
实施例8:本发明中药组合提取物对高血压模型大鼠的影响
一、实验动物:SD大鼠50只,雌雄各半,体重240-260g,从北京维通利华实验动物技术有限公司购入。
二、实验药物及分组:分组为假手术组、模型组、低剂量治疗组、高剂量治疗组、性对照组。取本发明实施例5中制备得到的中药组合提取物作为治疗组所用药物,低剂量治疗组、高剂量治疗组的给药剂量分别为2 g/kg、4 g/kg;阳性对照组给与卡托普利溶液,给药剂量为5 mg/kg,假手术组和模型组分别给予4 g/kg的生理盐水。
三、实验方法:取上述40只SD大鼠,雌雄各半,腹腔注射3%戊巴比妥钠进行麻醉,在腹部正中纵向切口,钝性分离两侧肾动脉,穿入无菌丝线,将针灸针与肾动脉血管长轴紧贴平行放置,用无菌丝线扎紧肾动脉和针灸针,然后抽出针灸针,造成两侧肾动脉狭窄,另外取6只大鼠经相同手术过程但未进行结扎,作为假手术组。手术造模2周后测定血压,以收缩压超过150 mmHg为造模成功,筛选出造模成功的24只高血压模型大鼠,随机分成模型组(4g/kg生理盐水)、低剂量治疗组(剂量为2 g/kg)、高剂量治疗组(剂量为4 g/kg)给予本发明实施例5中制备的中药组合提取物,以及阳性对照组(5 mg/kg卡托普利),每组6只。各组大鼠均进行灌胃给药,每天给药1次,连续给药4周,在给药开始的第0、2和4周测定各组大鼠的收缩压和舒张压。
四、实验结果:
(1)对高血压大鼠收缩压的影响
结果如表4所示,可见,与假手术组相比,在给药开始前(第0周)各组大鼠造模后的收缩压均显著升高。与模型组相比,给药2周和4周后低、高剂量组大鼠的收缩压显著降低,且高剂量组的疗效优于阳性对照组。
表4 对肾性高血压大鼠收缩压的影响(平均数±标准差,mmHg)
(2)对高血压大鼠舒张压的影响
结果如表5所示,可以看出,与假手术组相比,在给药开始前(第0周)各组大鼠造模后的舒张压均显著升高。与模型组相比,给药2周和4周后低、高剂量组大鼠的舒张压显著降低,且高剂量组的疗效优于阳性对照组。
表5 对肾性高血压大鼠舒张压的影响(平均数±标准差,mmHg)
综上,从实验结果可以看出,本发明中药组合提取物低、高剂量组均对高血糖、高血脂、高尿酸、高血压模型大鼠具有显著治疗作用,且高剂量组的治疗作用优于阳性对照组,说明书本发明中药组合提取物具有显著的同时降 “四高”的治疗作用,且制备方法简单,制成的口服液易于服用。
申请人声明,本发明通过上述实施例来说明本发明的一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法和应用,但本发明并不局限于上述实施例,即不意味着本发明必须依赖上述实施例才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
以上详细描述了本发明的优选实施方式,但是,本发明并不限于上述实施方式中的具体细节,在本发明的技术构思范围内,可以对本发明的技术方案进行多种简单变型,这些简单变型均属于本发明的保护范围。
另外需要说明的是,在上述具体实施方式中所描述的各个具体技术特征,在不矛盾的情况下,可以通过任何合适的方式进行组合,为了避免不必要的重复,本发明对各种可能的组合方式不再另行说明。
Claims (10)
1.一种降血糖、血脂、血压、尿酸的中药组合提取物,其特征在于,中药原料为:萆薢10-30份、冬瓜皮5-25份、山楂5-25份、羊蹄10-30份、麦冬5-25份、天麻5-20份、石斛5-20份、女贞子10-25份、香薷10-30份、蔓荆子5-25份、桑叶5-20份。
2.根据权利要求1所述的中药组合提取物,其特征在于,中药原料为:萆薢15-30份、冬瓜皮10-25份、山楂10-25份、羊蹄15-30份、麦冬10-25份、天麻8-20份、石斛8-20份、女贞子12-25份、香薷15-30份、蔓荆子8-23份、桑叶8-18份。
3.根据权利要求2所述的中药组合提取物,其特征在于,中药原料为:萆薢25份、冬瓜皮20份、山楂25份、羊蹄28份、麦冬22份、天麻16份、石斛15份、女贞子14份、香薷25份、蔓荆子15份、桑叶15份。
4.根据权利要求2所述的中药组合提取物,其特征在于,中药原料为:萆薢30份、冬瓜皮22份、山楂25份、羊蹄26份、麦冬20份、天麻15份、石斛13份、女贞子21份、香薷20份、蔓荆子20份、桑叶16份。
5.如权利要求 1-4任一项所述的中药组合提取物的制备方法,其特征在于,包括以下步骤:
S1.按重量份取桑叶,除杂后真空干燥,再粉碎为粗粉,过80-100目筛,加入粗粉总重量4-8倍量的去离子水,在40-60℃下超声提取1-3次,每次1-4 h,超声提取的功率为110-180W,提取完成后合并滤液,过滤得到桑叶提取液,备用;
S2.按重量份取萆薢、冬瓜皮、山楂、羊蹄、麦冬、天麻、石斛、女贞子、香薷、蔓荆子,清洗干净后真空干燥,再粉碎为粗粉,过60-80目筛,过筛后将上述粗粉加入至步骤S1中得到的桑叶提取液中,煮沸后小火继续煎煮1.5-5 h,过滤,得到滤液备用,滤渣加入2-5倍量的去离子水煮沸后继续煎煮0.5-3 h,过滤得到滤液,合并两次滤液,室温下冷却,得到中药提取液,备用;
S3.取上述中药提取液,经150-250目筛过滤得滤液,真空浓缩至原来体积的1/2-1/3,加入甜菊糖调味,混合均匀得混合药液,即得所述中药组合提取物。
6.如权利要求5所述的中药组合提取物的制备方法,其特征在于,将所述中药组合提取物制备为口服液:取所述中药组合提取物,灌封至玻璃口服液瓶中,灌装轧盖后,紫外灭菌10-30 min,包装,即得所述口服液。
7.如权利要求5所述的中药组合提取物的制备方法,其特征在于,步骤S1中过90目筛,超声提取2次,第1次加入6倍量的去离子水提取4 h,第2次加入4倍量去离子水提取2 h。
8.如权利要求5所述的中药组合提取物的制备方法,其特征在于,步骤S1中提取温度为50℃,提取功率为150W。
9.如权利要求5所述的中药组合提取物的制备方法,其特征在于,步骤S2中第1次煎煮时间为4 h,第2次为2.5 h。
10.一种如权利要求1-9任一项中所述的中药组合提取物在制备降血糖、血脂、血压、尿酸的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311389433.6A CN117244021B (zh) | 2023-10-25 | 一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311389433.6A CN117244021B (zh) | 2023-10-25 | 一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117244021A true CN117244021A (zh) | 2023-12-19 |
CN117244021B CN117244021B (zh) | 2024-07-16 |
Family
ID=
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102078402A (zh) * | 2011-01-13 | 2011-06-01 | 侯平照 | 治疗高血压、高血脂和高血糖的中药组合物 |
CN104757356A (zh) * | 2015-03-11 | 2015-07-08 | 陈航 | 一种辅助降血糖的组合物及其制备方法、制剂与应用 |
CN107801990A (zh) * | 2017-11-30 | 2018-03-16 | 杭州海王生物工程有限公司 | 一种辅助降血糖的保健食品及其制备方法 |
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102078402A (zh) * | 2011-01-13 | 2011-06-01 | 侯平照 | 治疗高血压、高血脂和高血糖的中药组合物 |
CN104757356A (zh) * | 2015-03-11 | 2015-07-08 | 陈航 | 一种辅助降血糖的组合物及其制备方法、制剂与应用 |
CN107801990A (zh) * | 2017-11-30 | 2018-03-16 | 杭州海王生物工程有限公司 | 一种辅助降血糖的保健食品及其制备方法 |
Non-Patent Citations (5)
Title |
---|
李国莺等: "萆薢总皂苷调节血脂与抗动脉粥样硬化作用的实验研究", 中国药学杂志, vol. 56, no. 23, 31 December 2021 (2021-12-31), pages 1899 * |
李茜;李运伦;: "调肝方五首治疗青年高血压", 山东中医杂志, vol. 32, no. 04, 5 April 2013 (2013-04-05), pages 250 - 252 * |
李路;高晟;: "中药治疗高脂血症100方分析", 世界中西医结合杂志, vol. 11, no. 07, 28 July 2016 (2016-07-28), pages 910 - 913 * |
苗琦;方文娟;张晓毅;罗光明;: "江香薷化学成分及药理作用研究进展", 江西中医药大学学报, vol. 27, no. 02, 15 April 2015 (2015-04-15), pages 119 * |
邱进;王晓静;王元书;丁杏苞;: "桑叶化学成分的研究", 中成药, vol. 30, no. 09, 20 September 2008 (2008-09-20), pages 1 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN105749179A (zh) | 治疗代谢综合征的中药组合物 | |
CN104352887A (zh) | 一种具有抗肿瘤综合调养膏方及制备工艺 | |
CN105031517A (zh) | 一种降三高的铁皮石斛保健茶及其制备方法 | |
CN108277138A (zh) | 一种保健养生酒及其制备方法 | |
CN103690784B (zh) | 治疗糖尿病肾病合并高血压肾病的中药组合物及制备方法 | |
CN102885975B (zh) | 一种治疗糖尿病的中药组合物 | |
CN102940730A (zh) | 治疗高血压的中药 | |
CN108066712A (zh) | 一种补气养血中药组合物 | |
CN103705860B (zh) | 一种治疗婴幼儿黄疸的中药组合物及其制备方法 | |
CN106109521A (zh) | 一种三七口服液 | |
CN105851395A (zh) | 一种黄芪养生茶及其制备方法 | |
CN110538311A (zh) | 一种用于控制高血压的纯中药组合物及其制备方法 | |
CN111135235A (zh) | 一种预防和缓解急性酒精中毒或醉酒的组合物 | |
CN117244021B (zh) | 一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法 | |
CN101745042B (zh) | 一种具有解酒保肝作用的组合物及其制备方法 | |
CN106362067A (zh) | 一种刺梨健胃消食药物组合物及其制备方法 | |
CN117244021A (zh) | 一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法 | |
CN111658720A (zh) | 用于养生的中药组合物、养生丸以及制备方法 | |
CN104857121A (zh) | 一种治疗高血脂症的药物组合物及其应用 | |
CN104623615A (zh) | 一种治疗哮喘的药物 | |
CN112823807A (zh) | 一种阿胶人参膏及其制备方法 | |
CN106177476A (zh) | 一种包含石斛和陈皮的降血糖保健组合物 | |
CN104800600A (zh) | 一种治疗高血压的药物 | |
CN104606570A (zh) | 一种适宜糖尿病患者服用的消渴代茶饮及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |